Une « mutation » de l’art ? Martin Heidegger et Paul Klee

Ce texte se penche sur le rôle décisif que Heidegger attribue à l’œuvre de Paul Klee. Au regard de l’histoire métaphysique de l’art, Klee représenterait la possibilité d’une « mutation » et d’un dépassement, qui nécessiterait par ailleurs la rédaction d’une seconde partie de la conférence sur l’œuvre d’art. En examinant le lien qui unit la métaphysique et l’image, en même temps que le sens de la « fin de l’art » à l’âge de la métaphysique achevée, on montre en quoi l’œuvre de Klee fait contrepoint à cette détermination métaphysique de l’art. Dans cette perspective, les analogies entre les textes de Heidegger et ceux de Klee tendent à confirmer le statut de ce dernier comme peintre de l’« autre commencement ». Il convient néanmoins de circonscrire la portée de telles analogies, en montrant comment, à côté d’une œuvre théorique encore partiellement soumise à des cadres philosophiques traditionnels, c’est par son œuvre plastique que Klee peut infléchir le sens de la conférence sur l’œuvre d’art du côté de l’autre commencement.This study examines the decisive role that Heidegger attributed to Paul Klee’s work. Regarding the metaphysical history of art, Klee’s work would represent the possibility of a “mutation” and of going further, which would in turn require the writing of a second part of the conference on the work of art. By examining the link between metaphysics and image, as well as the meaning of the “end of art” in the age of metaphysics, I show how Klee’s work offers an alternative to this metaphysical determination of art. In this perspective, the analogies between Heidegger’s texts and those of Klee tend to confirm the latter’s status as the painter of the “other beginning”. Nevertheless, such analogies should be carefully circumscribed, showing how, besides a theoretical work still partially subject to traditional philosophical frameworks, Klee’s plastic work can influence the meaning of the lecture on the work of art as a part of the other beginning

Ontologie et anthropologie de l’historique

Karl Löwith est l’auteur d’un ouvrage bien connu, Histoire et salut, dont le sous-titre, « Les présupposés théologiques de la philosophie de l’histoire », paraît dire l’essentiel. Pourtant, s’il s’agit bien dans ce livre – et dans les textes qui l’accompagnent dans le tome 2 des Schriften de Löwith – de dégager l’arrière-plan de la « philosophie de l’histoire », qui la fait envisager comme « sécularisation » d’un patrimoine spirituel judéo-chrétien, son enjeu est plus profondément de dépasser..

Le Corbusier: Architecture as a project of the world approach to a philosophy of architecture

La arquitectura moderna como un producto humano, ayudado por la técnica, da respuesta a las necesidades humanas en el proceso de habitar el mundo. El punto central es la revisión de un “proyecto de mundo” que para algunos maquinizó el problema del habitar y para otros apostó por la esencia antropológica que subyace a la necesidad de dar expresión material a un mejor mundo humano habitable. Este trabajo no procurará entonces hacer una “reivindicación” de Le Corbusier, pues a cada momento histórico le corresponden diversas respuestas a través de los productos humanos que dan cuenta de condiciones particulares de las culturas; se trata más bien de hacer una “reinterpretación” del proyecto de mundo que se gestó con el movimiento moderno de la arquitectura y, particularmente, con Le CorbusierThis article is a result of the reflection around the modern architecture as a human product than, supported by technical, gives answers to the human needs in the process of living in the world. The point is the search and reinterpretation of a “world project” that has been considered the “machining” of the world inhabit by some, and, for others, has been understood as a an movement that opted for the anthropological essence behind the need to give material expression to the human inhabit. This paper does not seek to make a “claim” to rescue Le Corbusier, as I am aware that each historical period has different answers by human products that account for conditions in the cultures, which clearly would not make sense to emulate; rather what I tried to make a “reinterpretation” of the proposed world was conceived with the modern movement in architecture and, particularly, with Le Corbusie

Prospective Evaluation of Ultrasonic Surgical Dissectors in Hepatic Resection: A Cooperative Multicenter Study

Blood loss is the major cause of postoperative mortality and morbidity associated with hepatic resection. A prospective multicenter study was conducted to determine if ultrasonic dissectors (USD) were useful in hepatic resection and could reduce this hemorrhagic risk. Forty-seven hepatic resections were performed in 42 consecutive patients during a two month period in 11 public, surgical centers. Twenty-one patients had primary or secondary malignancies, six had benign tumors, two had biliary cysts, one had cholangiocarcinoma, one had Caroli’s disease, and 11 had hydatid cysts of the liver. Two different USD devices were evaluated (CUSA System-Lasersonics and NIIC-DX 101 T). The hepatic resections tested included a wide range of procedures. Each surgeon had the possibility of choosing between the USD and his own usual technique for each operative step and according to local conditions. The average volume of blood infused, irrespective of the underlying pathology or the procedure performed, was 1.0 L (range 0-4.8 L). Fourteen patients required no transfusions. No operative or immediate postoperative deaths were recorded. Five major complications, all unrelated to the use of the USD, developed in three patients. Access to intra and extraparenchymal arterial and venous tributaries and particularly the control of the hepatic veins were facilitated by USD. While transection of hepatic parenchyma was neither easier nor faster than with conventional techniques, it was found to be less hemorrhagic. Overall appraisal was expressed on an analog scale; the USD was found to be helpful or very helpful in 75 percent of all resections. With regard to the pathology being treated, total or partial excision of hydatid cysts was greatly enhanced by the use of the USD while this benefit was not found for wedge resections of other hepatic lesions. With regard to user friendliness and maintenance, the NIIC-DX 101 T device was preferred. We conclude that the USD facilitates formal hepatic resections. Converging opinions emerging from various surgical centers reinforce this conclusion

Successful Arterial Embolisation of Giant Liver Haemangioma

A 28-year old man presented with a symptomatic giant haemangioma. On June 26, 1983, at laparotomy, no resection was attempted because the lesion involved the right lobe of the liver and a part of segments II and III. The patient underwent a right hepatic arterial embolisation with gelatine sponge particles. During follow-up, the patient remained asymptomatic. Five-year review by CT-scan showed a diminution of the size of the haemangioma and hypertrophy of the left lobe. On October 21, 1988, the patient was reoperated on for liver abscess and complete necrosis of the haemangioma. A right hepatectomy was performed. In conclusion, the long-term effect of hepatic arterial embolisation, as demonstrated in our case by regular CT-scans, is useful in cases of diffuse haemangioma as an alternative to hazardous major liver resection. To our knowledge, the long-term effect of hepatic arterial embolisation on symptoms and tumor size have never been reported for giant liver haemangioma

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Advanced solid tumors; Pharmacokinetics; Antitumor activityTumors sòlids avançats; Farmacocinètica; Activitat antitumoralTumores sólidos avanzados; Farmacocinética; Actividad antitumoralPurpose: Tusamitamab ravtansine is an antibody–drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a cytotoxic maytansinoid payload. In a phase I dose-escalation study, the maximum tolerated dose (MTD) was 100 mg/m2 every 2 weeks (Q2W). Here we report results for two alternative schedules. Experimental Design: Adults ages ≥18 years (range, 34–73) with locally advanced/metastatic solid tumors (N = 43; colon/rectum, 29; stomach, 7; pancreas, 4; other, 3) expressing/likely to express CEACAM5 received intravenous tusamitamab ravtansine 120–170 mg/m2 [loading dose (LD)], then 100 mg/m2 Q2W (Q2W-LD, n = 28), or 120–190 mg/m2 fixed dose [every 3 weeks (Q3W), n = 15]. The primary endpoint was dose-limiting toxicities (DLTs) during cycles 1–2 (Q2W-LD) and cycle 1 (Q3W). Results: Reversible DLTs were observed in 2 of 9 patients (grade 2 keratopathy; grade 2 keratitis) with 170 mg/m2 in Q2W-LD and in 2 of 3 patients (grade 2 keratopathy; grade 3 transaminase elevation) with 190 mg/m2 in Q3W. Nineteen (67.9%) patients in Q2W-LD and 13 (86.7%) patients in Q3W experienced treatment-related adverse events (AE); 3 of 43 patients discontinued treatment because of AEs. The most common AEs were asthenia, gastrointestinal complaints, keratopathy, keratitis, and peripheral sensory neuropathy. In this small, heavily pretreated population, no confirmed responses were observed; however, stable disease occurred in 35.7% of patients in Q2W-LD and 40.0% of patients in Q3W. Conclusions: Tusamitamab ravtansine had a favorable safety profile with both alternative administration schedules; MTDs were 170 mg/m2 (LD) followed by 100 mg/m2 Q2W, and 170 mg/m2 Q3W as a fixed dose. (NCT02187848). Significance: The collective results of this phase I dose-escalation study will inform further studies of tusamitamab ravtansine in patients with solid tumors with CEACAM5 expression, including patients with non–small cell lung cancer.This work was supported by Sanofi. Medical writing support was provided by Blair Jarvis and Elizabeth Strickland of inScience Communications (Philadelphia, PA). This work was performed in accordance with current Good Publication Practice guidelines and funded by Sanofi

Middle Segment Pancreatectomy: A Useful Tool in the Management of Pancreatic Neoplasms

Small, benign, or low-grade malignant tumors located in the neck of the pancreas are usually treated with enucleation. However, if enucleation is too risky because of possible damage of the main pancreatic duct, standard pancreatic resections are performed. Such operations can lead to impaired long-term exocrine–endocrine function. Middle segment pancreatectomy consists of a limited resection of the midportion of the pancreas and can be performed in selected patients affected by tumors of the pancreatic neck. Middle segment pancreatectomy is a safe and feasible procedure for treating tumors of the pancreatic neck; in experienced hands it is associated with no mortality but with high morbidity, even if the rate of “clinical” pancreatic fistula is about 20%. Moreover, it allows a surgeon to preserve pancreatic parenchyma and consequently long-term endocrine and exocrine pancreatic function